4 hours Exelixis Beats on Q3 Earnings and Sales, Raises Annual OutlookZacks
EXEL tops on earnings and sales in the third quarter as lead drug Cabometyx maintains momentum. The company also raises its revenue guidance for 2024.
X NYSE Nasdaq 100 Earnings Tech SEC Science U.S. Politics Business AI Energy Dow Jones Wall Street Dividend Investing Crude Oil Markets Wealth China Economy Real Estate Insurance S&P 500 Health Software Canada World Natural Gas Tesla (TSLA) NVIDIA (NVDA) 3M (MMM) Fed Bitcoin (BTC) Gold Inflation Money Entertainment Pharmaceuticals Construction Options U.K. Retail Boeing (BA) Apple (AAPL) JPMorgan (JPM) Security Wells Fargo&Co (WFC) Mining Truist Financial Corp (TFC) Amazon (AMZN) Current Europe Goldman Sachs (GS) Retirement Jim Cramer Hedge Funds Meta Platforms (META) Manufacturing Microsoft (MSFT) Aerospace Google Netflix (NFLX) Bank of America (BAC) Taxes Morgan Stanley (MS) Finance Sports Silver Enterprise Elon Musk York Airlines New York Donald Trump Cars Tax Economics Israel Internet REITs Live Japan Compound (COMP) Milton Citigroup (C) Ontario Life Insurance Mortgage Interest Rates Texas Costco (COST) Property BlackRock (BLK) Space Boston Florida IPOs ASML (ASML) Electronics ChemicalsMore +
